Varegacestat

Small molecule

Filedunder review

Evidence outlook · regulatory review

Desmoid Tumors: application under FDA review, decision date 2027-04-28

FDA accepts the NDA for varegacestat in desmoid tumors (2026-07-08). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

RINGSIDE (NCT04871282): This was a randomized, quadruple-masked Phase 2/3 trial with 198 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-12-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Source for the program status

Company guidance: regulatory filing expected by the end of 2026 (Immunome, Inc., 11 Aug 2026). “Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Desmoid Tumors
Phase 1 (5)
Other / comorbidity
NCT07610005 · Immunome, Inc.
2026-05-21 – 2027-05 · Healthy
What this study did
NCT06841315 · Immunome, Inc.
2025-03-07 – 2026-03-06 · Healthy Volunteer, Hepatic Impairment (HI)
What this study did
NCT06677996 · Immunome, Inc.
2024-11-11 – 2025-05-07 · Healthy Volunteer
What this study did
NCT06855264 · Immunome, Inc.
2025-02-24 – 2025-05-06 · Healthy Volunteer
What this study did
NCT06845852 · Immunome, Inc.
2025-02-25 – 2025-03-26 · Healthy Volunteer
What this study did

Competitive landscape

Other Gamma-secretase (presenilin complex) drugs

Nirogacestat. Compare all 2 Gamma-secretase (presenilin complex) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Desmoid Tumors: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Varegacestat: this drugPhase 2/3Small moleculeGamma-secretase (presenilin complex)Partial signal
NCT04871282: Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15).
NirogacestatApprovedSmall moleculeGamma-secretase (presenilin complex)Reliable signalNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Varegacestat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
Phase 1HealthyRecruiting
Est. primary completion 2027-05 · NCT07610005 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 April 2027FDA action datePDUFA target action date for the varegacestat NDA
US, FDA · FDA · Source ↗

Recent

30 October 2026Filing acceptedEMA validates the varegacestat MAA in desmoid tumors
EU, EMA · Source ↗
8 July 2026Filing acceptedFDA accepts the NDA for varegacestat in desmoid tumors
US, FDA · Immunome, Inc. · Source ↗
15 December 2025Topline resultPhase 3 RINGSIDE meets primary endpoint of progression-free survival
Immunome, Inc. · Source ↗